Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.

NPJ systems biology and applications - 15 May 2024

De Carli Alice, Kapelyukh Yury, Kursawe Jochen, Chaplain Mark A J, Wolf C Roland, Hamis Sara

Abstract excerpt

In vertical inhibition treatment strategies, multiple components of an intracellular pathway are simultaneously inhibited. Vertical inhibition of the BRAFV600E-MEK-ERK signalling pathway is a standard of care for treating BRAFV600E-mutated melanoma where two targeted cancer drugs, a BRAFV600E-inhibitor, and a MEK inhibitor, are administered in combination. Targeted therapies have been linked to early onsets of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 38750040
DOI: 10.1038/s41540-024-00379-9
PMCID: PMC11096323

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.PMID 38750040Read ↗

Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.Semantic proximity Read ↗

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistanceSemantic proximity Read ↗

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.Semantic proximity Read ↗

Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancersSemantic proximity Read ↗

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance.Semantic proximity Read ↗

Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.Semantic proximity Read ↗

Overcoming Resistance to BRAF <sup>V600E</sup> Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network AlterationsSemantic proximity Read ↗

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Semantic proximity Read ↗

Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.Semantic proximity Read ↗

Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.Semantic proximity Read ↗

Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaSemantic proximity Read ↗

Multiobjective Optimization Identifies Cancer-Selective Combination TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.